

NOVATHON

KISQALI[®] ribociclib NEWS WORTH SHARING

AGENDA

MARCH 28TH - 30TH 2025, QOSMO HOTEL, BRAȘOV

DAY 1 - MARCH 29TH, 2025

09:00 – 09:10 Welcome

- Marcelo Rainer,
Country President Novartis Romania

**MODERATORS: DR. DAN JINGA
& DR. NICOLETA ANTONE**

09:10 – 10:45 Part I - eBC Patient Journey

09:10 – 09:25 Clinical experience

- Dr. Simona Volovăț

09:25 – 09:45 A Surgical Spotlight in Early Breast Cancer – diagnosis

- Dr. Dan Eniu

09:45 – 10:05 Surgical options in breast cancer – from a minimum to a maximum

- Dr. Alexandru Blidaru

10:05 – 10:25 Cracking the code: biomarker testing in early and advanced/metastatic breast cancer

- Dr. Bogdan Fetica

10:25 – 10:45 Facing the facts: current landscape & opportunities in breast cancer treatment in Romania

Panel discussion:

- Dr. Simona Volovăț • Dr. Dan Eniu

- Dr. Alexandru Blidaru • Dr. Bogdan Fetica

10:45 – 11:00 Coffee Break

11:00 – 13:00 Part II – News worth sharing

11:00 – 11:20 Understanding the Risk of Recurrence in Early Breast cancer

- Dr. Dana Stănculeanu

11:20 – 11:40 Zoom-in analysis: risk of recurrence in eBC in IRO Iasi

- Dr. Vlad Afrăsânie

11:40 – 12:00 CDK4/6i in Early Breast Cancer: Insights and Opportunities from the NATALEE Trial

- Dr. Petra Tesarova

12:00 – 12:20 News worth sharing: Key data and clinical implications based on NATALEE Trial

- Dr. Mark Verrill

12:20 – 13:00 Unlocking new opportunities for eBC patients

Panel discussion:

- Dr. Dana Stănculeanu • Dr. Vlad Afrăsânie

- Dr. Petra Tesarova • Dr. Mark Verrill

13:00 – 14:00 Lunch Break

14:00 – 16:00 Part III – Discover Kisqali Powerful consistency

14:00 – 14:20 NATALEE Efficacy in Subgroups: How Prior Systemic Treatment Shapes Outcomes

- Dr. Dana Grecea

14:20 – 14:40 NATALEE's Impact on Patient Subgroups: NO vs N+

- Dr. Michael Untch

14:40 – 15:00 CDK4/6i benefits in age-subgroups for eBC patients

- Dr. Ayelet Shai

15:00 – 15:20 Safety and Adherence – What to expect from Kisqali in adjuvant setting

- Dr. Oana Trifănescu

15:20 – 16:00 Applying Natalee data for treating at-risk patients.

Panel discussion:

- Dr. Michael Untch • Dr. Dana Grecea

- Dr. Ayelet Shai • Dr. Oana Trifănescu

- Dr. Cornelia Nițipir • Dr. Dan Jinga

- Dr. Nicoleta Antone

16:00 – 16:15 Coffee break

**MODERATORS: DR. DAN JINGA
& DR. CORNELIA NIȚIPİR**

16:15 – 17:30 Part IV – Kisqali mBC Bridging Evidence and Experience

16:15 – 16:30 Clinical case presentation

- Dr. Răzvan Negreanu

16:30 – 16:45 Clinical case presentation

- Dr. Marius Păduraru

16:45 – 17:00 Clinical case presentation

- Dr. Crina Chirodea

17:00 – 17:30 National & International perspectives on BC treatment

Panel discussion:

- Dr. Shai • Dr. Verrill • Dr. Tesarova

- Dr. Dan Jinga • Dr. Nicoleta Antone

- Dr. Cornelia Nițipir

NOVATHON

NEWS YOU HAVE SEEN COMING:  PLUVICTO®
lutetium (¹⁷⁷Lu) vipivotide tetraxetan

AGENDA

MARCH 30TH 2025, QOSMO HOTEL, BRAȘOV

DAY 2 - MARCH 30TH, 2025

- 09:00 – 09:05** **Welcome & Intro to Day 2**
- 09:05 – 09:10** **Opening and meeting objectives**
• Dr. Gabriel Kacso
- 09:10 – 11:00** **Session 1 – NEWS YOU HAVE SEEN COMING**
Prostate Cancer Imaging and Treatment in the Theranostic Era
Moderator: • Dr. Gabriel Kacso
- 09:10 – 09:25** **Envisioning Landscape of Prostate Cancer Management in Personalized medicine era. Romanian reality zoom-in**
• Dr. Gabriel Kacso
- 09:25 – 09:40** **PSMA-targeted Radiopharmaceuticals for Prostate Cancer Diagnostic & Treatment**
• Dr. Andrei Gafita
- 09:40 – 09:55** **Diagnostic Value of PSMA-PET**
• Dr. Paolo Castellucci
- 09:55 – 10:10** **Imaging in Prostate Cancer Now and Tomorrow**
• Dr. Nina Tunariu
- 10:10 – 10:25** **Pluvicto - The PSMA Radioligand Therapy**
• Dr. Daniela Lager-Oprea
- 10:25 – 11:05** **Patient Selection & Outcome Prediction with ¹⁷⁷Lu-PSMA-617 Experience Sharing**
• Vision criteria vs TheraP criteria
• FDG PET, WB MRI & PSMA tumor heterogeneity
• Tools for clinical decision making – predictive and/or prognostic nomograms
• Association between quantitative Ga68 PSMA PET & treatment response
• ¹⁷⁷Lu-PSMA-617 in pre-chemo setting
• Working in MDT – is this a reality?
• Clinical cases discussion
Panel discussion:
• Dr. Daniela Lager-Oprea • Dr. Nina Tunariu
• Dr. Andrei Gafita • Dr. Paolo Castellucci
• Dr. Gabriel Kacso
- 11:05 – 11:20** **COFFEE BREAK**
- 11:20 – 13:25** **Session 2 – PRACTICALS WORTH SHARING**
Theranostic Strategies for PC Treatment. A Practical Perspective
Moderators: • Dr. Raluca Mititelu
• Dr. Gabriel Kacso
- 11:20 – 12:30** **Treatment Response Assessment With ¹⁷⁷Lu-PSMA. Experience Sharing**
• PSMA RLT in the guidelines
• Combination with ARPI
• Dosimetry in the spotlight – do we need all “6”?
• Monitoring patients on PSMA RLT
• SPECT in practice
• Sequencing after ¹⁷⁷Lu-PSMA
• Clinical cases discussions
Panel lecturers:
• Dr. Daniela Lager-Oprea • Dr. Nina Tunariu
• Dr. Andrei Gafita • Dr. Paolo Castellucci
• Dr. Raluca Mititelu • Dr. Gabriel Kacso
- 12:30 – 13:45** **Setting up a Theranostic Center**
• Theranostics in practice
• Does FDG & PSMA PET-CT work together in the same center?
• HotLab in focus. Maintaining the Environment
• RLTCare – a Novartis solution
• Local Radiological Safety Rules – where do we stand in PSMA RLT
Panel lecturers:
• Trabelsi Moez • Pharm.Tech. John Watters
• Stefania Bosi • Costin Ghioca
• Dr. Daniela Lager-Oprea • Dr. Nina Tunariu
• Dr. Andrei Gafita • Dr. Paolo Castellucci
• Dr. Raluca Mititelu • Dr. Gabriel Kacso
- 13:25 – 13:30** **CLOSING NOVARTIS EVENT**